Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 179.28M | 157.37M | 130.20M | 119.25M | 115.78M |
| Total Other Revenue | -- | 100.00K | 100.00K | 100.00K | 100.00K |
| Total Revenue | 179.28M | 157.47M | 130.30M | 119.35M | 115.88M |
| Cost of Revenue | 42.03M | 37.58M | 31.12M | 28.62M | 31.63M |
| Gross Profit | 137.25M | 119.89M | 99.18M | 90.73M | 84.25M |
| SG&A Expenses | 113.06M | 110.39M | 108.20M | 106.46M | 105.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.09M | 147.97M | 139.32M | 135.08M | 137.37M |
| Operating Income | 24.19M | 9.50M | -9.02M | -15.73M | -21.49M |
| Income Before Tax | 18.37M | 3.88M | -14.23M | -19.80M | -25.09M |
| Income Tax Expenses | 881.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.49 | 3.88 | -14.23 | -19.80 | -25.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.49M | 3.88M | -14.23M | -19.80M | -25.09M |
| EBIT | 24.19M | 9.50M | -9.02M | -15.73M | -21.49M |
| EBITDA | 26.42M | 11.42M | -7.42M | -14.45M | -20.25M |
| EPS Basic | 0.99 | 0.22 | -0.81 | -1.14 | -1.44 |
| Normalized Basic EPS | 0.65 | 0.14 | -0.51 | -0.75 | -0.94 |
| EPS Diluted | 0.94 | 0.18 | -0.85 | -1.17 | -1.47 |
| Normalized Diluted EPS | 0.64 | 0.14 | -0.51 | -0.75 | -0.94 |
| Average Basic Shares Outstanding | 70.32M | 70.11M | 69.94M | 69.75M | 69.59M |
| Average Diluted Shares Outstanding | 70.70M | 70.16M | 69.95M | 69.76M | 69.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |